Details of issuance or disposal
Monthly exercise status of Series 58 and Series 66 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clauses)
Number of shares issued during the month covered: Series 66: 0 shares; Series 58: 0 shares
Exercise ratio during the month covered: 0%. Exercise ratio subject to the exercise restriction: 0%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of Series 58 and Series 66 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Number of shares to be issued or disposed of | Number of shares issued during the month covered: Series 66: 0 shares; Series 58: 0 shares |
| Intended allottee | Name EVO FUND / Subject Series 66 stock acquisition rights / Number of Shares Not disclosed, Name CVI Investments, Inc. / Subject Series 58 stock acquisition rights / Number of Shares Not disclosed |
| Dilution Rate | Exercise ratio during the month covered: 0%. Exercise ratio subject to the exercise restriction: 0% |
| Total number of issued shares | 71,868,505 shares (including 90,965 treasury shares) → Not disclosed |
| Exercise price | Series 66: Exercise prices during the month covered were ¥115, ¥107, ¥121, ¥118, ¥114, etc. Series 58: ¥86. Floor under the exercise price adjustment clause: not disclosed |
| Number of Stock Acquisition Rights | Series 66: Total issued, 200,000 rights; unexercised at month-end, 200,000 rights. Series 58: Total issued, 20,000 rights; unexercised at month-end, 20,000 rights |
| Procedures under the Corporate Code of Conduct | The status of compliance with the exercise restriction under Article 434 of the Listing Regulations is stated. The total number of shares issued across all series was 0 shares, the number of listed shares as of the payment date for the issuance was 48,855,455 shares, and the exercise ratio subject to the exercise restriction was 0%. |
| Most recent equity financing | Timing 1 June 2022 / Type Issuance of new shares and Series 58 stock acquisition rights through a third-party allotment / Amount Not disclosed, Timing 12 August 2025 / Type Issuance through a third-party allotment of Series 65 through Series 67 stock acquisition rights (with exercise price adjustment clauses), and execution of a purchase agreement for the Series 1 unsecured ordinary bonds and stock acquisition rights (commitment issue) / Amount Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status for March 2026. With respect to the Series 58 stock acquisition rights, the issuance of Series 65 through Series 67 stock acquisition rights caused them to be deemed “MSCBs, etc.” under the regulations of the Tokyo Stock Exchange, making disclosure of their monthly exercise status necessary. Disclosure of the monthly exercise status of the Series 67 stock acquisition rights has been omitted because, under the purchase agreement, they are structured so that they generally cannot be exercised until 13 August 2027.